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Insulin-like growth factor binding proteins (IGFBPs) modulate IGF action. Proteolytic leavage of IGFBPs yields lower molecular forms with 
reduced ability to bind IGFs, thereby increasing IGF bioavailability. In serum from normal adult rats, we found a proteolytic activity for IGFBP-3, 
presumably a cation-dependent serine protease. It is lacking in serum from hypophysectomized rats and restored by infusion of growth hormone 
(GH), but not IGF I. Thus, IGF I does not appear to mediate the GH effect on IGFBP-3 proteolysis. Rather, GH seems to modulate IGF action 
indirectly via alteration of IGFBP-3 structure. 
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1. INTRODUCTION 
Insulin-like growth factor binding proteins comprise 
a family of 6 homologous proteins (IGFBP-1 to -6) 
found both in the circulation and in tissues [1,2]. 
IGFBP-3 is the most abundant binding protein in serum 
of adult rats and humans. After binding IGF, it aggre- 
gates with an acid-labile subunit (ALS) to form an M r 
150,000 ternary complex [3-5]. About 80% of serum 
IGF I and II are found in this complex. In the hypophy- 
sectomized rat, both IGF I and growth hormone are 
capable of increasing serum levels of IGFBP-3, whereas 
the formation of the ternary serum complex is propa- 
gated only by GH [6]. IGFBPs increase the half-life of 
IGFs and modulate IGF action in an inhibitory [7 9] 
or stimulatory [10-12] fashion. IGFBPs are substrates 
for proteases which appear in the serum under several 
physiological and pathological conditions: proteolytic 
degradation of IGFBP-3 (and other IGFBPs) was first 
observed in human and rat pregnancy [13-15]. IGFBP- 
3 degrading activity is also detected in serum from pa- 
tients with prostatic ancer [16] and from patients after 
elective surgery [17]. Proteolysis of IGFBPs yields trun- 
cated molecules with reduced ability to bind IGFs, 
thereby possibly increasing IGF bioavailability. Re- 
cently, prostate-specific antigen [18] and plasmin [19] 
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have been identified as IGFBP proteases. Recent stud- 
ies also suggest hat GH and/or IGF regulate IGFBP 
proteases: upon electrophoresis of serum from 
acromegalic patients, a band probably representing 
truncated IGFBP-3 can be detected [20], and IGFBP-4 
proteolytic activity in fibroblast conditioned media de- 
pends on the presence of IGF [21,22]. We investigated 
the role of GH and IGF I in the proteolytic degradation 
of IGFBP-3. Hypox rats were used as an in vivo model. 
2. MATERIALS AND METHODS 
2.1. Animals" 
5- to 6-week-old male Tif RAI rats were hypophysectomized (cour- 
tesy of K. Mfiller and M. Cortesi, Ciba-Geigy, Basel). Alzet osmotic 
minipumps (model 2001, Alza, Palo Alto, CA) were implanted sub- 
cutaneously 2 weeks after hypophysectomy in 15 animals whose body 
weight had not increased more than 2 g/week. Five animals each were 
infused with vehicle (0.9% NaC1/0.1 M acetic acid), with 200 mU/ 
rat x day of rhGH (Nordisk, Gentofte, Denmark) dissolved in 0.9% 
NaC1, or with 300/lg/rat x day of rhIGF I (gift of Drs. K. Mfiller and 
W. M~rki, Ciba Geigy, Basel) dissolved in 0.9% NaCI/0.1 M acetic 
acid. After 6 days, the animals were anesthetized with 0.3 ml/animal 
of Innovar Vet (Pitman-Moore, Washington Crossing, NJ ) and bled 
by aortic puncture. Aspirated blood was kept on ice for 30 rain, 
centrifuged, and serum was collected. Serum from untreated normal 
age-matched animals was obtained by the same procedure. Sera from 
the treated and 3 untreated animals and from 5 healthy non-pregnant 
and 5 term pregnant women were pooled and stored at -20°C until 
used. 
2.2. Western ligand analysis 
IGFBPs were identified by the method of Hossenlopp et al. [23] with 
slight modifications [6]. Briefly, 2/l l  of serum was subjected to 15% 
SDS-PAGE under non-reducing conditions. Separated proteins, in- 
cluding a molecular weight marker (Rainbow Marker, Amersham), 
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were electroblotted onto a nitrocellulose membrane. The membrane 
was incubated with approx. 4 x 106cpm of [125I]rhlGF II, washed, 
dried, and exposed to an X-ray film. 
! [ 2 ! 2.3. 1GFBP-3 proteolysis a says 
The method of Lamson et al. [24] was used with minor modifica- 
tions. Glycosylated [125I]rhlGFBP-3 (2 glycosylation variants with 
Mrof 42,000/45,000; approx, specific radioactivity 160 /tCi/mg) 
was obtained from Anawa Co., Dfibendorf, Switzerland. 50,000 cpm 
[~25I]rhlGFBP-3 (final concentration approx. 0.3 nM) was incubated 
with 5 ,ul of serum in a total volume of 20/A of phosphate- buffered 
saline (PBS), pH 7.4, containing l mM of CaC12. Additional agents 
were added as indicated, rhlGFBP-3 was kindly provided by Drs. A. 
Sommer and C. Maack, Celtrix, Santa Clara, CA. rhlGFBP-4, -5, and 
-6 were expressed in yeast and purified as described [25]. After 8 h at 
37°C, reactions were stopped by adding 20/4 of non-reducing sample 
buffer. Mixtures were subjected to 15% SDS-PAGE (constant voltage, 
35-65 V overnight). Gels were dried in a vacuum drier (Bio- Rad, 
Richmond, CA), and bands were visualized by autoradiography. 
2.4. Densitometry 
The relative optical densities (OD) of autoradiographic bands were 
measured with a densitometer (Model 620, Bio-Rad). To estimate the 
extent of [~25I]rhlGFBP-3 degradation, the areas under the OD peaks 
from intact and degraded IGFBP-3 were integrated with a computer 
program (1 D Analyst II, Bio-Rad). The integrated peaks of the 
relative ODs from cleavage product bands were expressed as percent- 
age of the total OD of all bands in each lane. 
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Fig. 2. SDS-PAGE of [~25I]rhlGFBP-3 after incubation for 8 h at 37 ° C 
with various erum pools. M, molecular weight marker; Lane 1, buffer 
control (con); lane 2, normal rat serum (NRS); lane 3, serum from 
hypox rats treated with vehicle (HRS); lane 4, serum from rhGH- 
treated hypox rats (HRS/GH); lane 5, serum from rhlGF I-treated 
hypox rats (HRS/IGF); lane 6, term pregnancy serum (TP); lane 7, 
non-pregnancy serum (NP); lane 8, heat-inactivated serum from 
rhGH-treated hypox rats (hi); lane 9, serum from rhGH-treated hypox 
rats in the presence of 5 mM EDTA. % Proteolysis (bottom line): the 
integrated peaks of the relative optical densities in the cleavage prod- 
uct bands are given as percentage ofthe total optical density in each 
lane. 
3. RESULTS 
3.1. Western ligand analysis of rat sera 
In hypox rats, serum levels of  IGFBP-3  are low (Fig. 
1). Both rhGH and rh IGF  I increase IGFBP-3  levels. 
Densitometr ic  quant i tat ion of  the bands shows a signif- 
icantly greater increase in IGFBP-3  levels in GH-  as 
compared to IGF  I- infused animals. 
3.2. Analysis of lGFBP-3 proteolytic activity in rat sera 
Fig. 2 shows the patterns of  intact and degraded 
[125I]rhIGFBP-3 obtained by incubat ion with various 
serum pools. Incubat ion with serum from normal  adult  
rats yields three distinct bands of  degraded IGFBP-3  
with approx. Mr of  30,000, 22,000, and 17,000 besides 
the Mr 42,000/45,000 doublet  of  intact IGFBP-3.  The 
degradat ion products are barely detectable after incu- 
bat ion with serum from vehicle- or IGF  I - treated hypox 
Mrx l0  -3 1 2 3 4 5 6 7 8 9 10 
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AUC 23_+035 903+0.55  14 .07_+269 147 
Fig. 1. Western ligand blot from individual hypox and treated hypox 
rat sera. Each lane shows the IGFBP-3 signal ('triplet'), representing 
3 different glycosylation variants. Lanes 1 3, vehicle-treated hypox 
rats (HRS); lanes 4-6, rhlGF I-treated hypox rats (HRS/IGF); lanes 
7-9, rhGH-treated hypox rats (HRS/GH); lane 10, serum pooled from 
3 normal adult rats (NRS). AUC denominates the area under the 
relative OD peaks obtained by densitometric s anning of each triplet 
(mean _+ S.D.). 
rats, but they reappear after incubat ion with serum 
from GH-t reated hypox rats. Degradat ion  is prevented 
by boil ing the serum for 5 min pr ior  to the incubat ion 
or by the addit ion of  5 mM EDTA to the incubat ion 
mixture. The same Mr cleavage products are found after 
incubat ion of  [125I]rhIGFBP-3 with serum from term 
pregnant women. However, degradat ion is more pro- 
nounced than after incubation with rat sera. Human 
non-pregnancy serum contains no IGFBP-3  proteolyt ic 
activity. Cleavage of  radiolabeled rh lGFBP-3  by serum 
from GH-t reated hypox rats is completely abol ished by 
10 mM phenylmethylsulfonyl  f luoride (PMSF)  and 50 
mM benzamidine, two serine protease inhibitors, but 
not by 10 ¢tM leupeptine, a serine/cysteine protease in- 
hibitor (Fig. 3). The above concentrat ions of PMSF and 
benzamidine ffectively inhibit proteases in sera [24] or 
f ibroblast condit ioned media [21]. Proteolyt ic cleavage 
is detectable after 1 h incubation. It reaches its maxi- 
mum after 8 h. No further degradat ion appears after 18 
h. When radiolabeled rh lGFBP-3  is incubated at pH 3, 
the three typical degradat ion bands are no longer de- 
tectable (data not shown). 
To test the specificity of  the IGFBP-3-degrad ing ac- 
tivity, reactions were carried out in the presence and 
absence of  various concentrat ions of  unlabeled 
rh lGFBPs  (Fig. 4). Proteolysis of  [125I]rhlGFBP-3 by 
normal  rat serum is inhibited completely by 1 ¢tM 
rh lGFBP-3  and nearly completely by 1 ¢tM rh lGFBP-4  
and 5. In contrast,  rh lGFBP-6  does not inhibit degrada-  
t ion (upper panel). Identical results are found with 
serum from rhGH-t reated hypox rats (not shown). Pro- 
teolysis by human term pregnancy serum is competed 
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Fig. 3. SDS-PAGE of [J25I]rhlGFBP-3 after incubation for 8 h with 
various serum pools. M: molecular weight marker. Lane 1, buffer 
control (con); lane 2, serum from normal rats (NRS); lane 3, serum 
from hypox rats treated with vehicle (HRS); lanes 4~7, serum from 
rhGH-treated hypox rats (HRS/GH) in the absence (con) or presence 
of 10 mM PMSF; 50 mM benzamidine (BENZ) and 10,uM leupeptine 
(LEU). % Proteolysis (bottom line): the percentage ofprcteolysis for 
each lane, determined as described in Fig. 2. 
by 1 pM rhlGFBP-3,  but not by 1 ¢tM rhlGFBP-4,  -5, 
and -6 (lower panel), rh IGFBPs at 1 nM and bovine 
serum albumin in concentrations of  up to 10 pM (not 
shown) do not inhibit degradation. 
4. D ISCUSSION 
Normal  adult rat serum contains an enzymatic activ- 
ity that cleaves [~25I]rhlGFBP-3 into three proteolytic 
fragments. This serum activity is lacking in hypox rats 
and restored by rhGH-,  but not rh lGF  I infusion. Par- 
tial characterization of the activity suggests that it is a 
cation-dependent serine protease. However, we cannot 
conclude from our experiments whether GH exerts its 
effects on this activity by inducing the protease or by 
suppressing a putative enzyme inhibitor. 
A cation-dependent serine protease has been sug- 
gested to degrade IGFBP-3 in human term pregnancy 
serum [13,24]. However, IGFBP-3 proteolysis by 
human and rat serum differ in several aspects: (i) 
whereas the degradation of  radiolabeled IGFBP-3 by 
human term pregnancy serum is almost complete, it is 
incomplete with serum from normal or GH-treated 
hypox rats. A possible explanation for this is inhibition 
of  the enzyme by cleavage products, although we have 
no data to support this hypothesis; (ii) in contrast o rat 
serum, human non-pregnancy serum contains no prote- 
olytic activity; (iii) the activity found in human serum 
appears to be more specific than that in rat serum, since 
it can be competed only by an excess of  unlabeled 
IGFBP-3,  whereas other IGFBPs also inhibit degrada- 
tion by the rat serum protease. We conclude from these 
findings that the enzymes responsible for the degrada- 
tion of  IGFBP-3 by human term pregnancy and adult 
rat serum are different. 
The absence of IGFBP-3-degrading activity in serum 
from IGF  I-treated hypox rats could result from higher 
serum levels of  IGFBP-3 in IGF  I- as compared to 
GH-treated animals. High concentrations of  IGFBP-3 
would compete for the protease in our assay. However, 
as evidenced by the ligand analysis of  the rat sera (Fig. 
1), serum levels of  IGFBP-3 are even higher in the GH-  
than in the IGF  I-treated hypox rats. Thus, the prote- 
olytic serum activity is induced by GH, and its induction 
does not appear to be mediated by IGF  I. 
Disappearance of  the Mr 150,000 ternary complex 
with a concomitant shift of  IGF  to an Mr 40,000 IGF/  
IGFBP  complex and truncation of  IGFBPs are two 
independent mechanisms which can modulate IGF  bi- 
oavailability. For example, hypox rats lack the Mr 
150,000 ternary serum complex [6] and carry all serum 
IGF  in the M r 40,000 complex which, in contrast o the 
former, passes the capillaries. In these animals, intrave- 
nously injected IGF  has a much shorter half-life than 
in normal rats [8] and the animals are more susceptible 
to acute insulin-like effects of  IGF  I and II than normal 
rats [8]. Other studies suggest hat truncated IGFBPs 
bind IGFs  with lower affinity than the intact forms 
[14,26,27], although this has been challenged [28]. Thus, 
Mrx l0  "3 
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Fig. 4. SDS-PAGE of [125I]rhlGFBP-3 after incubation for 8 h with 
rat and human serum pools in the absence and presence of excess 
unlabeled rhlGFBPs. Upper panel: effects 1 ¢tM rhBP-3, -4, -5 and -6 
on proteolytic degradation of [125I]rhlGFBP-3 by normal rat serum 
(NRS). M, molecular weight marker; Con, buffer control. If the reac- 
tions were done with serum from rhGH-treated hypox rats, an identi- 
cal pattern of proteolytic bands was observed (not shown). Lower 
panel: effects of various concentrations of rhlGFBPs -3, -4, -5 and -6 
on proteolytic degradation ofradiolabeled rhlGFBP-3 by human term 
pregnancy serum. M and con, molecular weight marker and buffer 
control, respectively. 
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intravenously injected IGF  I has a longer serum elimi- 
nat ion half-life in non-pregnant  as compared to preg- 
nant rats, in which intact IGFBP-3  is dramatical ly  re- 
duced [15]. Our data provide evidence that proteolysis 
of  IGFBP-3  is under hormonal  control.  Thus, GH may 
augment concentrat ions of IGFs  both systemically and 
locally: (i) directly by inducing all components  of  the 
ternary serum complex ( IGF,  IGFBP-3,  and the acid- 
labile subunit, ALS)  and increasing IGF  synthesis in 
certain tissues; (ii) indirectly by inducing an IGFBP-3  
proteolyt ic activity, thereby facil itating the dissociation 
of IGF  from IGFBP-3,  which is a constituent of  the 
ternary complex both in its intact and truncated form 
[26,29,30]. 
Our study does not address the question to which 
extent ALS may protect IGFBP-3  from proteolysis. Ra- 
diolabeled IGFBP-3  is incorporated into the ternary 
serum complex [31]; however, it is unknown if degrada- 
tion occurs before or after complex formation. We sus- 
pect that ALS  has little, if  any, role in preventing enzy- 
matic degradat ion of  IGFBP-3:  a l though ALS  is pres- 
ent in 
GH- ,  but not in IGF  I- infused hypox rats [6], degra- 
dat ion occurs only in GH-t reated animals. Further-  
more, in humans, concentrat ions of  immunoreact ive 
ALS increase l inearly during pregnancy [29], whereas 
concomitant ly most of  the circulating IGFBP-3  is de- 
graded to lower molecular  weight forms. 
In conclusion, an IGFBP-3  proteolyt ic serum activ- 
ity, presumably a cat ion-dependent serine protease dis- 
tinct from that in human term pregnancy serum, corre- 
lates with the GH-status  of  adult  rats. Its induction by 
GH does not appear  to be mediated by IGF  I. Thus, 
GH may modulate IGF  actions by a mechanism distinct 
from effects on IGF  or IGF- receptor  concentrations. 
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